American Society of Hirudotherapy

Surface modification with PEG and hirudin for protein resistance and thrombin neutralization in blood contact

Research article published in Colloids and surfaces. B, Biointerfaces (2010)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Drug DevelopmentGenomics & ProteomicsAlibeik S, Zhu S, Brash J · Colloids and surfaces. B, Biointerfaces, 2010

Abstract

In this work, we hypothesize that a surface modified with both polyethylene glycol (PEG) and hirudin may provide a non-fouling, thrombin-neutralizing surface suitable for blood contacting applications. With gold as a model substrate we used two different approaches to the preparation of such a surface: (1) a "direct" method in which PEG was conjugated to hirudin and the conjugate was then immobilized on the gold; (2) a "sequential" method in which PEG was immobilized on the gold and hirudin then attached to the immobilized PEG. The surfaces were characterized by water contact angle, ellipsometry and XPS. The biological properties were investigated by measuring protein adsorption (fibrinogen and thrombin) from buffer and plasma; thrombin inhibition was measured using a chromogenic substrate assay. Hirudin immobilization was found to be more efficient on surfaces prepared by the "direct" method. "Sequential" surfaces, however, despite having a lower density of hirudin, showed greater biological activity (thrombin binding and inhibition).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsAdsorptionFibrinogenGoldHirudinsHumansSurface PropertiesThrombin

Summary

In this work, we hypothesize that a surface modified with both polyethylene glycol (PEG) and hirudin may provide a non-fouling, thrombin-neutralizing surface suitable for blood contacting applications.

Why This Matters for Hirudotherapy

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citation

Surface modification with PEG and hirudin for protein resistance and thrombin neutralization in blood contact.

Alibeik S, Zhu S, Brash J · Colloids and surfaces. B, Biointerfaces, 2010

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Surface modification with PEG and hirudin for protein resistance and thrombin neutralization in blood contact | ASH